Vertex's experimental pain drug fails main goal in mid-stage study
04/08/2025 21:06
Aug 4 (Reuters) - Vertex Pharmaceuticals VRTX.O said on Monday its next generation oral drug failed to meet the main goal of a keenly-watched mid-stage trial. (Reporting by Sriparna Roy and Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31